非酒精性脂肪性肝病和酒精性肝病中的肠道微生物群变化
Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.
作者信息
Kwong Eric K, Puri Puneet
机构信息
Department of Microbiology and Immunology, McGuire VA Medical Center, Richmond, VA, USA.
Section of Gastroenterology, Hepatology and Nutrition, McGuire VA Medical Center, Richmond, VA, USA.
出版信息
Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18. eCollection 2021.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are some of the most common liver diseases worldwide. The human gut microbiome is dynamic and shifts in bacterial composition have been implicated in many diseases. Studies have shown that there is a shift in bacterial overgrowth favoring pro-inflammatory mediators in patients with advanced disease progression such as cirrhosis. Further investigation demonstrated that the transplantation of gut microbiota from advanced liver disease patients can reproduce severe liver inflammation and injury in mice. Various techniques in manipulating the gut microbiota have been attempted including fecal transplantation and probiotics. This review focuses on the changes in the gut microbiota as well as emerging lines of microbiome work with respect to NAFLD and ALD.
摘要
非酒精性脂肪性肝病（NAFLD）和酒精性肝病（ALD）是全球最常见的一些肝脏疾病。人类肠道微生物群是动态的，细菌组成的变化与许多疾病有关。研究表明，在诸如肝硬化等疾病进展晚期的患者中，细菌过度生长出现了有利于促炎介质的转变。进一步的研究表明，将晚期肝病患者的肠道微生物群移植到小鼠体内可导致严重的肝脏炎症和损伤。人们尝试了各种操纵肠道微生物群的技术，包括粪便移植和益生菌。本综述重点关注肠道微生物群的变化以及在NAFLD和ALD方面微生物组研究的新进展。
相似文献
1
Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.非酒精性脂肪性肝病和酒精性肝病中的肠道微生物群变化
Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18. eCollection 2021.
2
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
3
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).用营养干预、益生菌、合生菌和粪便微生物群移植（FMT）来对抗脂肪肝疾病。
Adv Exp Med Biol. 2019;1125:85-100. doi: 10.1007/5584_2018_318.
4
The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.益生菌在非酒精性脂肪性肝病中的作用：治疗策略的新视角。
Nutrients. 2019 Nov 4;11(11):2642. doi: 10.3390/nu11112642.
5
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.肠道菌群与酒精性和非酒精性脂肪性肝病的新进展。
Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.
6
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.综述文章：细菌可以成为药物吗？益生菌和益生元作为非酒精性脂肪性肝病治疗手段的潜力。
Aliment Pharmacol Ther. 2019 Sep;50(6):628-639. doi: 10.1111/apt.15416. Epub 2019 Aug 2.
7
The role of the microbiome in NAFLD and NASH.微生物组在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
EMBO Mol Med. 2019 Feb;11(2). doi: 10.15252/emmm.201809302.
8
Alcohol, liver disease and the gut microbiota.酒精、肝病与肠道微生物组。
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):235-246. doi: 10.1038/s41575-018-0099-1.
9
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章：肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
10
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.调控非酒精性脂肪性肝病的肠道微生物组：益生菌、益生元、合生元和抗生素。
J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25.
引用本文的文献
1
Current and emerging therapies for alcohol-associated hepatitis.酒精性肝炎的现有及新兴疗法
Liver Res. 2023 Mar 15;7(1):35-46. doi: 10.1016/j.livres.2023.03.002. eCollection 2023 Mar.
2
Food for thought: Making the case for food produced via regenerative agriculture in the battle against non-communicable chronic diseases (NCDs).值得思考的问题：在对抗非传染性慢性病（NCDs）的斗争中，论证通过再生农业生产的食物的合理性。
One Health. 2024 Apr 20;18:100734. doi: 10.1016/j.onehlt.2024.100734. eCollection 2024 Jun.
3
Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection.载脂蛋白H在慢性乙型肝炎感染期间诱发性别特异性脂肪性肝炎和肠道菌群失调。
iScience. 2023 Feb 1;26(3):106100. doi: 10.1016/j.isci.2023.106100. eCollection 2023 Mar 17.
4
Gut Microbiota Deficiency Exacerbates Liver Injury in Bile Duct Ligated Mice via Inflammation and Lipid Metabolism.肠道微生物群缺乏通过炎症和脂质代谢加剧胆管结扎小鼠的肝损伤。
Int J Mol Sci. 2023 Feb 6;24(4):3180. doi: 10.3390/ijms24043180.
5
Current Medical Treatment for Alcohol-Associated Liver Disease.酒精性肝病的当前医学治疗方法。
J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1333-1348. doi: 10.1016/j.jceh.2022.02.001. Epub 2022 Feb 12.
6
Alcohol-dependent downregulation of apolipoprotein H exacerbates fatty liver and gut microbiota dysbiosis in mice.酒精依赖导致载脂蛋白 H 下调，加剧小鼠脂肪肝和肠道微生物失调。
Lipids Health Dis. 2022 Sep 19;21(1):89. doi: 10.1186/s12944-022-01699-7.
7
Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction.肠道FXR相关分子对胆道梗阻时肠黏膜屏障的影响
Front Pharmacol. 2022 Jun 13;13:906452. doi: 10.3389/fphar.2022.906452. eCollection 2022.
8
Alcoholic liver disease: a new insight into the pathogenesis of liver disease.酒精性肝病：对肝病发病机制的新认识。
Arch Pharm Res. 2022 Jul;45(7):447-459. doi: 10.1007/s12272-022-01392-4. Epub 2022 Jun 27.
9
The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study.肝硬化和非肝硬化患者小肠细菌过度生长、内毒素血症与肝脂肪变性和纤维化之间明显的不对称关系：一项单中心试点研究
Front Med (Lausanne). 2022 Apr 26;9:872428. doi: 10.3389/fmed.2022.872428. eCollection 2022.
10
The Gut Microbiota in Liver Transplantation Recipients During the Perioperative Period.肝移植受者围手术期的肠道微生物群
Front Physiol. 2022 Apr 1;13:854017. doi: 10.3389/fphys.2022.854017. eCollection 2022.
本文引用的文献
1
The Effectiveness of Personal Hygiene Practices on Non-Cuffed Central Vein Catheter-Related Infection in Patients Undergoing Hemodialysis: A Randomized Controlled Trial.个人卫生措施对接受血液透析患者非带袖套中心静脉导管相关感染的有效性：一项随机对照试验
Indian J Nephrol. 2019 Jul-Aug;29(4):267-271. doi: 10.4103/ijn.IJN_92_18.
2
Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.经活检证实的非酒精性脂肪性肝病患儿和青少年的糖尿病前期和糖尿病患病率。
J Hepatol. 2019 Oct;71(4):802-810. doi: 10.1016/j.jhep.2019.06.023. Epub 2019 Jul 4.
3
Impact of Noonan Syndrome on admissions for pediatric cardiac surgery.努南综合征对儿科心脏手术入院的影响。
Minerva Pediatr (Torino). 2022 Aug;74(4):461-467. doi: 10.23736/S2724-5276.19.05461-6. Epub 2019 Jun 28.
4
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.酒精性肝炎患者肠道真菌失调与真菌的全身免疫反应。
Hepatology. 2020 Feb;71(2):522-538. doi: 10.1002/hep.30832. Epub 2019 Aug 20.
5
The role of sphingosine kinase 2 in alcoholic liver disease.鞘氨醇激酶 2 在酒精性肝病中的作用。
Dig Liver Dis. 2019 Aug;51(8):1154-1163. doi: 10.1016/j.dld.2019.03.020. Epub 2019 Apr 16.
6
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
7
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis.优化非酒精性脂肪性肝病的非侵入性诊断：缩小检测晚期纤维化的差距
Hepatology. 2019 Mar;69(3):934-936. doi: 10.1002/hep.30402. Epub 2019 Feb 8.
8
FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice.法尼醇X受体（FXR）和G蛋白偶联胆汁酸受体5（TGR5）激动剂可改善小鼠暴饮或长期饮酒后的肝损伤、脂肪变性和炎症。
Hepatol Commun. 2018 Oct 15;2(11):1379-1391. doi: 10.1002/hep4.1256. eCollection 2018 Nov.
9
Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.在非酒精性脂肪性肝病患者中，肝脏 R2* 与质子密度脂肪分数的相关性强于组织学肝脏铁评分。
J Magn Reson Imaging. 2019 May;49(5):1456-1466. doi: 10.1002/jmri.26312. Epub 2018 Oct 14.
10
The Gut Microbiota and Dysbiosis in Autism Spectrum Disorders.肠道微生物群与自闭症谱系障碍中的失调。
Curr Neurol Neurosci Rep. 2018 Sep 24;18(11):81. doi: 10.1007/s11910-018-0887-6.
Zotero 插件